NervGen Pharma Corp is Shariah compliant. The company’s financials pass three standards and fail in two.
Ad
NGEN – NervGen Pharma Corp
Compliant
★★★☆☆
- Biotechnology & Medical Research
- Toronto Venture Exchange
- July 16, 2022
$80,522,616
Market cap
-
Revenue Growth
BUY
Analysts' Rating
AAOIFI
S&P
DJIM
FTSE
MSCI
AAOIFI
AAOIFI ✓
| Debt ÷ Market cap (MC) | 0% | ✓ |
| Non-Compliant Assets ÷ MC | % |
S&P
S&P ✓
| Debt ÷ 36 mo MC | 0% | ✓ |
| Cash ÷ 36 mo MC | 25.69% | ✓ |
| AR ÷ 36 mo MC | % |
DJIM
DJIM ✓
| Debt ÷ 24 mo MC | 0% | ✓ |
| Cash ÷ 24 mo MC | 21.73% | ✓ |
| AR ÷ 24 mo MC | % |
FTSE
FTSE ✗
| Debt ÷ Assets | 0% | ✓ |
| Cash ÷ Assets | 94.59% | ✗ |
| Cash&AR ÷ Assets | 94.59% | ✗ |
MSCI
MSCI ✗
| Debt ÷ Assets | 0% | ✓ |
| Cash ÷ Assets | 94.59% | ✗ |
| Cash&AR ÷ Assets | 94.59% | ✗ |
Ad
Recommendation Rating
2
1
2
3
4
5
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Analysts’ Price Targets
Mean 4.09
Low: 3.5
High: 4.67
Total Analysts: 1
Company Profile
NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. The Company has two wholly owned subsidiaries, including NervGen US Inc. and NervGen Australia Pty Ltd.
We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan.
Ad
Responses